BidaskClub upgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a buy rating to a strong-buy rating in a research note released on Thursday morning.
Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut Strongbridge Biopharma from a hold rating to a sell rating in a research report on Friday, March 16th. Cantor Fitzgerald reiterated a buy rating and set a $14.00 price target on shares of Strongbridge Biopharma in a research report on Monday, March 12th. Finally, HC Wainwright reiterated a buy rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $12.81.
Shares of Strongbridge Biopharma stock opened at $8.05 on Thursday. Strongbridge Biopharma has a 52-week low of $3.50 and a 52-week high of $9.02. The company has a debt-to-equity ratio of -3.17, a quick ratio of 4.84 and a current ratio of 4.88.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3298938/bidaskclub-upgrades-strongbridge-biopharma-sbbp-to-strong-buy.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.